The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward (Q38569186)

4 September 2017

title

The ASAS Criteria for Axial Spondyloarthritis: Strengths, Weaknesses, and Proposals for a Way Forward (English)

1 reference

4 September 2017

1

Sjef van der Linden

1 reference

4 September 2017

4

Philip C Robinson

1 reference

4 September 2017

Nurullah Akkoc

2

1 reference

4 September 2017

Matthew A Brown

series ordinal

3

1 reference

4 September 2017

Muhammad A Khan

series ordinal

5

1 reference

4 September 2017

publication date

1 September 2015

1 reference

Current Rheumatology Reports

4 September 2017

published in

1 reference

4 September 2017

volume

17

1 reference

4 September 2017

issue

9

1 reference

4 September 2017

page(s)

62

1 reference

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Update on spondyloarthropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Review: Nonradiographic axial spondyloarthritis: new definition of an old disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Identifying axial spondyloarthritis in Dutch primary care patients, ages 20-45 years, with chronic low back pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Methodological and statistical approaches to criteria development in rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Diagnosis and classification in spondyloarthritis: identifying a chameleon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Ankylosing spondylitis is associated with the anthrax toxin receptor 2 gene (ANTXR2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Recognition of preclinical and early disease in axial spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Autoantibodies against CD74 in spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

The changing clinical picture and epidemiology of spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Classification and diagnosis of axial spondyloarthritis--what is the clinically relevant difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Looking into the new ASAS classification criteria for axial spondyloarthritis through the other side of the glass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Distinctions between diagnostic and classification criteria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Susceptibility to ankylosing spondylitis in twins the role of genes, HLA, and the environment

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Development of classification and response criteria for rheumatic diseases

1 reference

https://api.crossref.org/works/10.1007%2FS11926-015-0535-Y

Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Occurrence of spinal pain syndromes in a group of apparently healthy and physically fit sportsmen (orienteers)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

CD74: a diagnostic key for spondyloarthritis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

Is disease severity in ankylosing spondylitis genetically determined?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

The diagnostic utility of magnetic resonance imaging in spondylarthritis: An international multicenter evaluation of one hundred eighty-seven subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/26286179

12 December 2020

10.1007/S11926-015-0535-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

1020988522

0 references

1 reference